SCHEMBL6929611

SCHEMBL6929611

CC(=O)N(Oc1ccc(Cl)cc1)c1ccc(C(=O)CCC(=O)O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.46
USP5 P45974 1/20 0.46
KMT2A Q03164 5/20 0.45
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
CYP1A2 P05177 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CYP2C19 P33261 2/20 0.44
PDE4B Q07343 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 2/20 0.43
NR4A2 P43354 1/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 2/20 0.41
FFAR1 O14842 1/20 0.41
HIF1A Q16665 1/20 0.41
MAPK1 P28482 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6926227 0.88 NR4A2 (0.53) MMP1USP5KMT2AALDH1A1HPGD
SCHEMBL6929812 0.86 PPARA (0.38) ALDH1A1HPGDL3MBTL1MAPTNR4A2
SCHEMBL6929808 0.86 PPARA (0.38) ALDH1A1HPGDL3MBTL1MAPTNR4A2
SCHEMBL27637403 0.79 KMT2A (0.51) MMP1USP5KMT2AALDH1A1HPGD
SCHEMBL10865120 0.78 MMP1 (0.69) MMP1USP5KMT2AALDH1A1HPGD
SCHEMBL392858 0.78 NR4A2 (0.65) MMP1USP5KMT2AALDH1A1HPGD
SCHEMBL6933215 0.74 PPARA (0.42) ALDH1A1MAPTMAPK1GAA
SCHEMBL7857464 0.73 SMN1; SMN2 (0.72) MMP1USP5KMT2AALDH1A1HPGD
SCHEMBL1304688 0.73 PPARA (0.69) KMT2AALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL13664137 0.71 MMP1 (0.68) MMP1KMT2AALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US claimed
US-6541521-B1 Particularly gelatinase A, collagenase-3, and stromelysin-1 WARNER-LAMBERT COMPANY 2003-04-01 US claimed
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2002-10-31 US claimed
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US disclosed
US-6541521-B1 Particularly gelatinase A, collagenase-3, and stromelysin-1 WARNER-LAMBERT COMPANY 2003-04-01 US disclosed
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2002-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases MMP1, MMP8, MMP13 MMP1 1/4885USP5 1850/4885KMT2A 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.